Author:
Polli James E.,Abrahamsson Bertil S. I.,Yu Lawrence X.,Amidon Gordon L.,Baldoni John M.,Cook Jack A.,Fackler Paul,Hartauer Kerry,Johnston Gordon,Krill Steve L.,Lipper Robert A.,Malick Waseem A.,Shah Vinod P.,Sun Duxin,Winkle Helen N.,Wu Yunhui,Zhang Hua
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. August 2000, CDER/FDA. http://www.fda.gov/cder/guidance/3618fnl.htm (accessed 12/15/07)
2. J. E. Polli, L. X. Yu, J. A. Cook, G. L. Amidon, R. T. Borchardt, B. A. Burnside, P. S. Burton, M.-L. Chen, D. P. Conner, J. Faustino, A. A. Hawi, A. S. Hussain, H. N. Joshi, G. Kwei, V. H. L. Lee, L. J. Lesko, R. A. Lipper, A. E. Loper, S. G. Nerurkar, J. W. Polli, D. R. Sanvordeker, R. Taneja, R. S. Uppoor, C. S. Vattikonda, I. Wilding, and G. Zhang. Summary workshop report: biopharmaceutics classification system—implementation challenges and extension opportunities. J. Pharm. Sci. 93:1375–1381 (2004).
3. Critical Path Opportunities Report. March 2006, FDA. http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf (accessed 12/15/07)
4. J. E. Polli. In vitro studies are sometimes better than conventional human in vivo studies in assessing bioequivalence for immediate-release solid oral dosage forms. AAPS J. in press (2008).
5. M. S. Ku. Use of the biopharmaceutical classification system in early drug development. AAPS J. in press (2008).
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献